FDA 483 - Sanofi-Aventis Deutschland GmbH - January 16, 2025

An FDA inspection of Sanofi-Aventis Deutschland GmbH, located in Frankfurt Am Main, Germany, was conducted from January 8-16, 2025. The inspection identified several significant observations concerning the facility's adherence to regulatory standards for drug substance and drug product manufacturing, particularly for sterile products.

Key issues highlighted include deficiencies in procedures designed to prevent microbiological contamination during aseptic filling operations. Specifically, environmental monitoring of critical and secondary product contact surfaces was found to be inadequate, and aseptic processing techniques were observed to be subpar, including the use of non-sterile gloves and compromised glove integrity. The validation of sterilization processes was also questioned due to improper placement of biological indicators.

Furthermore, the facility's drug substance manufacturing area for a specific product lacked sufficient environmental controls, such as pressure and humidity management, to assure product quality. The use of less stringent materials for product storage and handling, which did not meet quality assurance standards for a relevant product, was also noted.

Finally, the inspection revealed a lack of assurance regarding the effectiveness of cleaning procedures for product-contact equipment. Swab sampling, a critical component of cleaning validation to prevent product carryover and cross-contamination, was not performed for multi-product use equipment or specific drug substance manufacturing vessels.

These observations indicate the company must implement comprehensive corrective and preventive actions to establish and follow robust procedures for environmental control, aseptic processing, sterilization validation, and cleaning validation to ensure the sterility, quality, and purity of its drug products.